Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in‐situ hybridization in 510 patients
- 6 March 2008
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 141 (1) , 36-40
Abstract
Summary: CD20 is an important therapeutic target in chronic lymphocytic leukaemia (CLL). In order to examine the relationship between CD20 expression and cytogenetic abnormalities, we correlated the fluorescent in‐situ hybridization (FISH) genetic subtype of 510 treatment‐naïve patients with CD20 expression as measured by quantitative flow cytometry. Patients were classified using the Dohner hierarchial classification. The median numbers of CD20 antigen sites by FISH subtypes were: 17p‐ (n = 26), 9341 per cell; 11q‐ (n = 42), 5886 per cell; +12 (n = 93), 23 603 per cell; negative FISH (n = 153), 8828 per cell; and 13q‐ (n = 196), 10 781 per cell. Compared to cases with negative FISH, 11q‐ cases had significantly lower CD20 expression (P = 0·001), and +12 cases had significantly higher CD20 expression (P < 0·001). The significance of trisomy 12 and high CD20 expression was maintained after multivariate analysis accounting for other disease characteristics. Fifty‐nine patients received the combination of rituximab and granulocyte‐macrophage colony‐stimulating factor as frontline therapy; responses were observed in 13 of 14 (93%) patients with +12, in two of four (50%) patients with 11q‐, and in 30 of 41 (73%) patients with negative FISH, 13q‐ or 17p‐ CLL. Leukemic CD20 expression differed significantly between FISH subtypes. Patients with trisomy 12 CLL showed strong leukemic cell CD20 expression and had a high rate of response to rituximab‐based therapy.Keywords
This publication has 21 references indexed in Scilit:
- Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2005
- Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research NetworkJournal of Clinical Oncology, 2003
- Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significanceBlood, 2003
- Morphologically Typical and Atypical B-Cell Chronic Lymphocytic Leukemias Display a Different Pattern of Surface Antigenic DensityLeukemia & Lymphoma, 2001
- Genomic Aberrations and Survival in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2000
- Trisomy 12 is seen within a specific subtype of B‐cell chronic lymphoproliferative disease affecting the peripheral blood/bone marrow and co‐segregates with elevated expression of CD11aBritish Journal of Haematology, 1998
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994
- Detection of Trisomy 12 by FISH in Untreated B -Chronic Lymphocytic Leukemia: Correlation with Stage and CD20 Antigen Expression IntensityLeukemia & Lymphoma, 1994
- Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) AntibodyNew England Journal of Medicine, 1993
- Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemiaAmerican Journal of Hematology, 1992